2Panjrath GS, Patel V, Valdiviezo Ci, et al. Potentiation of doxorubicin cardiotoxicity by iron loading in a rodent model[ J]. J Am Coil Cardio1,2007,49 (25) :2457 - 2464.
3Deng S, Wojnowski L. Genotyping the risk of anthracycline-induced cardiotoxicity[ J ]. Cardiovasc Toxicol, 2007,7 ( 2 ) : 129 - 134.
4Wojnowski L, Kulle B, Schirmer G, et al. NAD (P) H oxidase and multidrug resistance protein genetic polymorphisras are associated with doxorubicin-induced cardiotoxicity [ J ]. Circulation ,2005,112 (24) :3754 - 3762.
5Germanakis I, Kalmanti M, Parthenakis F, et al. Correlation of plasma N-terminal pro-brain natriuretic peptide level with left ventricle mass in children treated with anthracyclines[ J]. Int J Cardiol,2006,108:212 -215.
6Malty M, Espie M, Llombart A, et al. Muhicenter randomized Phase Ⅲ study of the cardioprotective effect of dexrazoxane in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy[ J]. Ann Onco1,2006 ,17 :614 - 622.
7Sterba M, Popelova O, Simunek T, et al. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH) [ J ]. Toxicology ,2007,253 ( 3 ) : 150 - 166.
8Kaiserva H, Simunek T, van der Vijgh W J, et al. Flavonoids as protectors against doxorubicin cardiotoxicity : role of iron chelation, an-tioxidant activity and inhibition of carbonyl reductase [ J ]. Biochim Biophys Acta,2007,1772 : 1065 - 1074.
9Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the eardiotoxic mechanisms to management[ J], Prag Cardiovase Dis,2007,49 (5) :330 - 352.
10Saad SY, Najjar TA, Arafah MM. Cardioprotective effects of subcutaneous ebselen against daunorubicin-induced cardimyopathy in rats [ J ]. Basic Clin Pharmacol Toxico1,2006,99 (6) :412 - 417.
